


- 253 -

CLAIMS

1. A compound of the formula:




wherein:

A is an aryl group;

Q¹ is a covalent bond or an aryl leader group;

J is a sulfonamide linkage:

R¹ is a sulfonamido substituent; and,Q² is an acid leader group;

and wherein:

A, is a C₅₋₂₀aryl group, and is optionally substituted;

the aryl leader group, if present, is:

a C₁₋₇alkylene group;

and is optionally substituted;

the sulfonamido substituent, R¹, is:

hydrogen,

C₁₋₇alkyl,C₃₋₂₀heterocyclyl, orC₅₋₂₀aryl;the acid leader group, Q², is:phenylene -C₁₋₇alkylene; orC₁₋₇alkylene-phenylene;


and is optionally substituted;

and wherein the phenylene linkage is meta;

and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.

AMENDED SHEET

2. A compound according to claim 1, wherein the acid leader group, Q², is phenylene-C₁₋₇alkylene, and is optionally substituted.
3. A compound according to claim 1, wherein the acid leader group, Q², has the following formula, wherein R^{Q2} is C₁₋₇alkylene and the phenylene group is optionally substituted with m substituents, R^B, wherein m is an integer from 0 to 4:




4. A compound according to claim 3, wherein R^{Q2} is a saturated C₁₋₇alkylene group.
5. A compound according to claim 3, wherein R^{Q2} is a partially unsaturated C₁₋₇alkylene group.
6. A compound according to claim 3, wherein R^{Q2} is an aliphatic C₁₋₇alkylene group.
7. A compound according to claim 3, wherein R^{Q2} is a linear C₁₋₇alkylene group.
8. A compound according to claim 3, wherein R^{Q2} is a saturated aliphatic C₁₋₇alkylene group.
9. A compound according to claim 3, wherein R^{Q2} is a saturated linear C₁₋₇alkylene group.
10. A compound according to claim 3, wherein R^{Q2} is a partially unsaturated aliphatic C₁₋₇alkylene group.

- 255 -

11. A compound according to claim 3, wherein R^{Q2} is a partially unsaturated linear C_{1-7} alkylene group.
12. A compound according to claim 3, wherein R^{Q2} is selected from: $-CH_2-$, $-(CH_2)_2-$, $-(CH_2)_3-$, $-(CH_2)_4-$, $-(CH_2)_5-$, and $-(CH_2)_6-$, $-CH=CH-$, and $-CH=CH-CH=CH-$.
13. A compound according to claim 3, wherein R^{Q2} is cis or trans $-CH=CH-$.
14. A compound according to claim 3, wherein R^{Q2} is cis $-CH=CH-$.
15. A compound according to claim 3, wherein R^{Q2} is trans $-CH=CH-$.

* * *

16. A compound according to any one of claims 1 to 15, wherein the acid leader group, Q^2 , is unsubstituted.
17. A compound according to any one of claims 1 to 15, wherein the acid leader group, Q^2 , is substituted.
18. A compound according to any one of claims 1 to 15, wherein each R^B is independently selected from: fluoro, chloro, methyl, ethyl, isopropyl, t-butyl, trifluoromethyl, hydroxy, methoxy, ethoxy, isopropoxy, methylthio, amino, dimethylamino, diethylamino, morpholino, acetamido, nitro, and phenyl.
19. A compound according to claim 1, wherein the acid leader group, Q^2 , is:



* * *

AMENDED SHEET

- 256 -

20. A compound according to any one of claims 1 to 19, wherein Q¹ is an aryl leader group.
21. A compound according to any one of claims 1 to 19, wherein Q¹ is an aryl leader group and is a saturated C₁₋₇alkylene group and is optionally substituted.
22. A compound according to any one of claims 1 to 19, wherein Q¹ is an aryl leader group and is a partially unsaturated C₂₋₇alkylene group and is optionally substituted.
23. A compound according to any one of claims 1 to 19, wherein Q¹ is an aryl leader group and is an aliphatic C₁₋₇alkylene group and is optionally substituted.
24. A compound according to any one of claims 1 to 19, wherein Q¹ is an aryl leader group and is a linear C₁₋₇alkylene group and is optionally substituted.
25. A compound according to any one of claims 1 to 19, wherein Q¹ is an aryl leader group and is a saturated aliphatic C₁₋₇alkylene group and is optionally substituted.
26. A compound according to any one of claims 1 to 19, wherein Q¹ is an aryl leader group and is a saturated linear C₁₋₇alkylene group and is optionally substituted.
27. A compound according to any one of claims 1 to 19, wherein Q¹ is an aryl leader group and is a partially unsaturated aliphatic C₂₋₇alkylene group and is optionally substituted.
28. A compound according to any one of claims 1 to 19, wherein Q¹ is an aryl leader group and is a partially unsaturated linear C₂₋₇alkylene group and is optionally substituted.

AMENDED SHEET

29. A compound according to any one of claims 1 to 28, wherein Q¹ is an aryl leader group and has a backbone of at least 2 carbon atoms.
30. A compound according to any one of claims 1 to 28, wherein Q¹ is an aryl leader group and has a backbone of at least 3 carbon atoms.
31. A compound according to any one of claims 1 to 28, wherein Q¹ is an aryl leader group and has a backbone of from 2 to 7 carbon atoms.
32. A compound according to any one of claims 1 to 28, wherein Q¹ is an aryl leader group and has a backbone of from 3 to 7 carbon atoms.
33. A compound according to any one of claims 1 to 28, wherein Q¹ is an aryl leader group and has a backbone of 2 carbon atoms.
34. A compound according to any one of claims 1 to 28, wherein Q¹ is an aryl leader group and has a backbone of 3 carbon atoms.
35. A compound according to any one of claims 1 to 28, wherein Q¹ is an aryl leader group and has a backbone of 4 carbon atoms.
36. A compound according to any one of claims 1 to 28, wherein Q¹ is an aryl leader group and has a backbone of 5 carbon atoms.
37. A compound according to any one of claims 1 to 36, wherein Q¹ is an aryl leader group and is unsubstituted.

- 258 -

38. A compound according to any one of claims 1 to 36, wherein Q^1 is an aryl leader group and is substituted.
39. A compound according to any one of claims 1 to 36, wherein Q^1 is an aryl leader group and is unsubstituted or substituted with one or more groups selected from: halo, hydroxy, ether, C_{5-20} aryl, acyl, amido, and oxo.
40. A compound according to any one of claims 1 to 36, wherein Q^1 is an aryl leader group and is unsubstituted or substituted with one or more groups selected from: -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -OPr, -Ph, and =O.

41. A compound according to any one of claims 1 to 40, wherein Q^1 is an aryl leader group and is selected from $-CH_2-$, $-CH_2CH_2-$, $-CH_2CH_2CH_2-$, $-CH=CH-$, $-CH=CH-CH=CH-$, and C_5 cycloalkyl.
42. A compound according to any one of claims 1 to 40, wherein Q^1 is an aryl leader group and is selected from $-CH_2-$, $-CH_2CH_2-$, $-CH_2CH_2CH_2-$, $-CH=CH-$, and $-CH=CH-CH=CH-$.

43. A compound according to any one of claims 1 to 19, wherein Q^1 is a covalent bond.

44. A compound according to claim 1, wherein:
 Q^1 is an aryl leader group; and
 Q^2 is a phenylene-meta- C_1-C_7 alkylene group.

AMENDED SHEET

- 259 -

45. A compound according to claim 1, wherein:
 Q^1 is a covalent bond; and
 Q^2 is a phenylene-meta-C₁₋₇alkylene group.
46. A compound according to claim 1, wherein:
 Q^1 is a covalent bond or an aryl leader group having a backbone of at least 2 carbon atoms; and
 Q^2 is a phenylene-meta-C₁₋₇alkylene group.
47. A compound according to claim 1, wherein:
 Q^1 is an aryl leader group having a backbone of at least 2 carbon atoms; and
 Q^2 is a phenylene-meta-C₁₋₇alkylene group.

* * *

48. A compound according to claim 1, wherein:
 Q^1 is an aryl leader group; and
 Q^2 is a phenylene-meta-ethylene group.
49. A compound according to claim 1, wherein:
 Q^1 is a covalent bond; and
 Q^2 is a phenylene-meta-ethylene group.
50. A compound according to claim 1, wherein:
 Q^1 is a covalent bond or an aryl leader group having a backbone of at least 2 carbon atoms; and
 Q^2 is a phenylene-meta-ethylene group.
51. A compound according to claim 1, wherein:
 Q^1 is an aryl leader group having a backbone of at least 2 carbon atoms; and
 Q^2 is a phenylene-meta-ethylene group.

* * *

AMENDED SHEET

- 260 -

52. A compound according to any one of claims 1 to 51, wherein:
A is C₅₋₂₀heteroaryl or C₅₋₂₀carboaryl, and is optionally substituted.
53. A compound according to any one of claims 1 to 51, wherein:
A is a C₅₋₂₀aryl group derived from one of the following:
benzene, pyridine, furan, indole, pyrrole, imidazole, naphthalene, quinoline, benzimidazole, benzothiophuran, fluorene, acridine, and carbazole.
54. A compound according to any one of claims 1 to 51, wherein:
A is an optionally substituted phenyl group.
55. A compound according to any one of claims 1 to 51, wherein:
A is a phenyl group optionally substituted with one or more of the following groups:
fluoro, chloro, bromo, iodo, methyl, ethyl, isopropyl, t-butyl, cyano, trifluoromethyl, hydroxy, methoxy, ethoxy, isopropoxy, trifluoromethoxy, phenoxy, methylthio, trifluoromethylthio, hydroxymethyl, amino, dimethylamino, diethylamino, morpholino, amido, acetamido, acetyl, nitro, sulfonamido, and phenyl.

* * *

56. A compound according to any one of claims 1 to 55, wherein:
the sulfonamido substituent, R¹, is hydrogen, C₁₋₇alkyl, or C₅₋₂₀aryl.
57. A compound according to any one of claims 1 to 55, wherein:
the sulfonamido substituent, R¹, is hydrogen or C₁₋₇alkyl.
58. A compound according to any one of claims 1 to 55, wherein:
the sulfonamido substituent, R¹, is -H, -Me, or -Et.

- 261 -

59. A compound according to any one of claims 1 to 55, wherein:
the sulfonamido substituent, R¹, is -H.

60. Compound PX105684.
61. Compound PX105685.
62. Compound PX105844.
63. Compound PX106508.
64. Compound PX106509.
65. Compound PX106510.
66. Compound PX106511.
67. Compound PX106512.
68. Compound PX116238.
69. Compound PX117225.
70. Compound PX117226.
71. Compound PX117227.
72. Compound PX117228.
73. Compound PX117250.
74. Compound PX117445.
75. Compound PX117710.
76. Compound PX117712.
77. Compound PX117713.
78. Compound PX117715.
79. Compound PX117734.
80. Compound PX117735.
81. Compound PX117773.
82. Compound PX117774.
83. Compound PX117775.
84. Compound PX117778.
85. Compound PX117779.
86. Compound PX117782.
87. Compound PX117787.

AMENDED SHEET


- 262 -

88. Compound PX117788.
89. Compound PX117789.
90. Compound PX117790.
91. Compound PX117791.
92. Compound PX117796.
93. Compound PX117798.

AMENDED SHEET

WJW/LP5958467 - PCT Claims filed under Article 34 in Oct 2002 and before examination

94. A compound of the formula:





wherein:

A is an aryl group;

Q¹ is an aryl leader group;

J is a sulfonamide linkage selected from:



R¹ is a sulfonamido substituent; and,

Q² is an acid leader group;

and wherein:

A, is a C₅₋₂₀aryl group, and is optionally substituted;
the aryl leader group, is:

a C₂₋₇alkylene group

having a backbone of at least 2 carbon atoms;

and is optionally substituted;

the sulfonamido substituent, R¹, is:

hydrogen,

C₁₋₇alkyl,

C₃₋₂₀heterocyclyl, or

C₅₋₂₀aryl;

the acid leader group, Q², is:

phenylene -C₁₋₇alkylene; or

C₁₋₇alkylene-phenylene;

and is optionally substituted;

and wherein the phenylene linkage is meta or para;

and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.

95. A compound according to claim 94, wherein J is $-S(=O)_2NR^1-$.
96. A compound according to claim 94, wherein J is $-NR^1S(=O)_2-$.

97. A compound according to any one of claims 94 to 96, wherein Q^1 is a saturated C_{2-7} alkylene group and is optionally substituted.
98. A compound according to any one of claims 94 to 96, wherein Q^1 is a partially unsaturated C_{2-7} alkylene group and is optionally substituted.
99. A compound according to any one of claims 94 to 96, wherein Q^1 is an aliphatic C_{2-7} alkylene group and is optionally substituted.
100. A compound according to any one of claims 94 to 96, wherein Q^1 is a linear C_{2-7} alkylene group and is optionally substituted.
101. A compound according to any one of claims 94 to 96, wherein Q^1 is a saturated aliphatic C_{2-7} alkylene group and is optionally substituted.
102. A compound according to any one of claims 94 to 96, wherein Q^1 is a saturated linear C_{2-7} alkylene group and is optionally substituted.
103. A compound according to any one of claims 94 to 96, wherein Q^1 is a partially unsaturated aliphatic C_{2-7} alkylene group and is optionally substituted.
104. A compound according to any one of claims 94 to 96, wherein Q^1 is a partially unsaturated linear C_{2-7} alkylene group and is optionally substituted.

- 265 -

105. A compound according to any one of claims 94 to 104, wherein Q^1 has a backbone of at least 3 carbon atoms.
106. A compound according to any one of claims 94 to 104, wherein Q^1 has a backbone of from 2 to 7 carbon atoms.
107. A compound according to any one of claims 94 to 104, wherein Q^1 has a backbone of from 3 to 7 carbon atoms.
108. A compound according to any one of claims 94 to 104, wherein Q^1 has a backbone of 2 carbon atoms.
109. A compound according to any one of claims 94 to 104, wherein Q^1 has a backbone of 3 carbon atoms.
110. A compound according to any one of claims 94 to 104, wherein Q^1 has a backbone of 4 carbon atoms.
111. A compound according to any one of claims 94 to 104, wherein Q^1 has a backbone of 5 carbon atoms.

112. A compound according to any one of claims 94 to 111, wherein Q^1 is unsubstituted.
113. A compound according to any one of claims 94 to 111, wherein Q^1 is substituted.

- 266 -

114. A compound according to any one of claims 94 to 111, wherein Q^1 is unsubstituted or substituted with one or more groups selected from: halo, hydroxy, ether, C_{5-20} aryl, acyl, amido, and oxo.

115. A compound according to any one of claims 94 to 111, wherein Q^1 is unsubstituted or substituted with one or more groups selected from: -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -OPr, -Ph, and =O.

* * *

116. A compound according to any one of claims 94 to 96, wherein Q^1 is selected from $-CH_2CH_2-$, $-CH_2CH_2CH_2-$, $-CH=CH-$, $-CH=CH-CH=CH-$, and C_5 cycloalkyl.


117. A compound according to any one of claims 94 to 96, wherein Q^1 is selected from $-CH_2CH_2-$, $-CH_2CH_2CH_2-$, $-CH=CH-$, and $-CH=CH-CH=CH-$.

* * *

118. A compound according to any one of claims 94 to 117, wherein the acid leader group, Q^2 , is phenylene-meta- C_{1-7} alkylene or phenylene-para- C_{1-7} alkylene, and is optionally substituted.

* * *

119. A compound according to any one of claims 94 to 117, wherein the acid leader group, Q^2 , has the following formula, wherein R^{Q2} is C_{1-7} alkylene and the phenylene group is optionally substituted with m substituents, R^B , wherein m is an integer from 0 to 4:



AMENDED SHEET

WJW/LP5958467 - PCT Claims filed under Article 34 in Oct 2002 and before examination

- 267 -

120. A compound according to claim 119, wherein R^{Q2} is a saturated C_{1-7} alkylene group.
121. A compound according to claim 119, wherein R^{Q2} is a partially unsaturated C_{1-7} alkylene group.
122. A compound according to claim 119, wherein R^{Q2} is an aliphatic C_{1-7} alkylene group.
123. A compound according to claim 119, wherein R^{Q2} is a linear C_{1-7} alkylene group.
124. A compound according to claim 119, wherein R^{Q2} is a saturated aliphatic C_{1-7} alkylene group.
125. A compound according to claim 119, wherein R^{Q2} is a saturated linear C_{1-7} alkylene group.
126. A compound according to claim 119, wherein R^{Q2} is a partially unsaturated aliphatic C_{1-7} alkylene group.
127. A compound according to claim 119, wherein R^{Q2} is a partially unsaturated linear C_{1-7} alkylene group.
128. A compound according to claim 119, wherein R^{Q2} is selected from: $-CH_2-$, $-(CH_2)_2-$, $-(CH_2)_3-$, $-(CH_2)_4-$, $-(CH_2)_5-$, and $-(CH_2)_6-$, $-CH=CH-$, and $-CH=CH-CH=CH-$.
129. A compound according to claim 119, wherein R^{Q2} is cis or trans $-CH=CH-$.
130. A compound according to claim 119, wherein R^{Q2} is cis $-CH=CH-$.

AMENDED SHEET

- 268 -


131. A compound according to claim 119, wherein R^{Q2} is trans -CH=CH-.

132. A compound according to any one of claims 119 to 131, wherein each R^B is independently selected from: fluoro, chloro, methyl, ethyl, isopropyl, t-butyl, trifluoromethyl, hydroxy, methoxy, ethoxy, isopropoxy, methylthio, amino, dimethylamino, diethylamino, morpholino, acetamido, nitro, and phenyl.

133. A compound according to any one of claims 94 to 131, wherein the acid leader group, Q^2 , is unsubstituted.

134. A compound according to any one of claims 94 to 131, wherein the acid leader group, Q^2 , is substituted.

135. A compound according to any one of claims 94 to 117, the acid leader group, Q^2 , is:



136. A compound according to claim 94, wherein:

J is $-S(=O)_2NR^1-$; and

Q^2 is a phenylene-meta- C_{1-7} alkylene group.

137. A compound according to claim 94, wherein:

J is $-NR^1S(=O)_2-$; and

AMENDED SHEET

- 269 -

Q² is a phenylene-meta-C₁₋₇alkylene group.

* * *

138. A compound according to claim 94, wherein:

J is -S(=O)₂NR¹-; and

Q² a phenylene-meta-ethylene group.

139. A compound according to claim 94, wherein:

J is -NR¹S(=O)₂-; and

Q² a phenylene-meta-ethylene group.

* * *

140. A compound according to any one of claims 94 to 139, wherein:

A is C₅₋₂₀heteroaryl or C₅₋₂₀carboaryl, and is optionally substituted.

141. A compound according to any one of claims 94 to 139, wherein:

A is a C₅₋₂₀aryl group derived from one of the following:

benzene, pyridine, furan, indole, pyrrole, imidazole, naphthalene, quinoline, benzimidazole, benzothiophuran, fluorene, acridine, and carbazole.

142. A compound according to any one of claims 94 to 139, wherein:

A is an optionally substituted phenyl group.

143. A compound according to any one of claims 94 to 139, wherein:

A is a phenyl group optionally substituted with one or more of the following groups:

fluoro, chloro, bromo, iodo, methyl, ethyl, isopropyl, t-butyl, cyano, trifluoromethyl, hydroxy, methoxy, ethoxy, isopropoxy, trifluoromethoxy, phenoxy, methylthio, trifluoromethylthio, hydroxymethyl, amino, dimethylamino, diethylamino, morpholino, amido, acetamido, acetyl, nitro, sulfonamido, and phenyl.

AMENDED SHEET

- 270 -

* * *

144. A compound according to any one of claims 94 to 143, wherein:
the sulfonamido substituent, R¹, is hydrogen, C₁₋₇alkyl, or C₅₋₂₀aryl.
145. A compound according to any one of claims 94 to 143, wherein:
the sulfonamido substituent, R¹, is hydrogen or C₁₋₇alkyl.
146. A compound according to any one of claims 94 to 143, wherein:
the sulfonamido substituent, R¹, is -H, -Me, or -Et.
147. A compound according to any one of claims 94 to 143, wherein:
the sulfonamido substituent, R¹, is -H.

* * *


148. Compound PX106512.
149. Compound PX117446.
150. Compound PX117735.
151. Compound PX117774.
152. Compound PX117779.

AMENDED SHEET

WJW/LP5958467 - PCT Claims filed under Article 34 in Oct 2002 and before examination

- 271 -

153. A compound of the formula:




wherein:

A is an aryl group;

Q¹ is a covalent bond or an aryl leader group;

J is a sulfonamide linkage:

R¹ is a sulfonamido substituent; and,Q² is an acid leader group;

and wherein:

A, is a C₅₋₂₀aryl group, and is optionally substituted;

the aryl leader group, if present, is:

a C₁₋₇alkylene group;

and is optionally substituted;

the sulfonamido substituent, R¹, is:

hydrogen,

C₁₋₇alkyl,C₃₋₂₀heterocyclyl, orC₅₋₂₀aryl;the acid leader group, Q², is:C₄₋₇alkylene

having a backbone length of from 4 to 7 carbon atoms;

and is optionally substituted;

and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.

* * *

- 272 -

154. A compound according to claim 153, wherein Q¹ is an aryl leader group.
155. A compound according to claim 153, wherein Q¹ is an aryl leader group and is a saturated C₁₋₇alkylene group and is optionally substituted.
156. A compound according to claim 153, wherein Q¹ is an aryl leader group and is a partially unsaturated C₂₋₇alkylene group and is optionally substituted.
157. A compound according to claim 153, wherein Q¹ is an aryl leader group and is an aliphatic C₁₋₇alkylene group and is optionally substituted.
158. A compound according to claim 153, wherein Q¹ is an aryl leader group and is a linear C₁₋₇alkylene group and is optionally substituted.
159. A compound according to claim 153, wherein Q¹ is an aryl leader group and is a saturated aliphatic C₁₋₇alkylene group and is optionally substituted.
160. A compound according to claim 153, wherein Q¹ is an aryl leader group and is a saturated linear C₁₋₇alkylene group and is optionally substituted.
161. A compound according to claim 153, wherein Q¹ is an aryl leader group and is a partially unsaturated aliphatic C₂₋₇alkylene group and is optionally substituted.
162. A compound according to claim 153, wherein Q¹ is an aryl leader group and is a partially unsaturated linear C₂₋₇alkylene group and is optionally substituted.
163. A compound according to any one of claims 153 to 162, wherein Q¹ is an aryl leader group and has a backbone of at least 2 carbon atoms.

* * *

163. A compound according to any one of claims 153 to 162, wherein Q¹ is an aryl leader group and has a backbone of at least 2 carbon atoms.

AMENDED SHEET

- 273 -

164. A compound according to any one of claims 153 to 162, wherein Q^1 is an aryl leader group and has a backbone of at least 3 carbon atoms.
165. A compound according to any one of claims 153 to 162, wherein Q^1 is an aryl leader group and has a backbone of from 2 to 7 carbon atoms.
166. A compound according to any one of claims 153 to 162, wherein Q^1 is an aryl leader group and has a backbone of from 3 to 7 carbon atoms.
167. A compound according to any one of claims 153 to 162, wherein Q^1 is an aryl leader group and has a backbone of 2 carbon atoms.
168. A compound according to any one of claims 153 to 162, wherein Q^1 is an aryl leader group and has a backbone of 3 carbon atoms.
169. A compound according to any one of claims 153 to 162, wherein Q^1 is an aryl leader group and has a backbone of 4 carbon atoms.
170. A compound according to any one of claims 153 to 162, wherein Q^1 is an aryl leader group and has a backbone of 5 carbon atoms.

* * *

171. A compound according to any one of claims 153 to 170, wherein Q^1 is an aryl leader group and is unsubstituted.
172. A compound according to any one of claims 153 to 170, wherein Q^1 is an aryl leader group and is substituted.
173. A compound according to any one of claims 153 to 170, wherein Q^1 is an aryl leader group and is unsubstituted or substituted with one or more groups selected from: halo, hydroxy, ether, C_{5-20} aryl, acyl, amido, and oxo.

AMENDED SHEET

- 274 -

174. A compound according to any one of claims 153 to 170, wherein Q¹ is an aryl leader group and is unsubstituted or substituted with one or more groups selected from: -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -OPr, -Ph, and =O.

* * *

175. A compound according to claim 153, wherein Q¹ is an aryl leader group and is selected from -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, -CH=CH-, -CH=CH-CH=CH-, and C₅cycloalkyl.

176. A compound according to claim 153, wherein Q¹ is an aryl leader group and is selected from -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, -CH=CH-, and -CH=CH-CH=CH-.

* * *

177. A compound according to claim 153, wherein Q¹ is a covalent bond.

* * *

178. A compound according to any one of claims 153 to 177, wherein the acid leader, Q², is a saturated linear C₄₋₇alkylene group.

* * *

179. A compound according to any one of claims 153 to 178, wherein the acid leader group, Q² is substituted.

180. A compound according to any one of claims 153 to 178, wherein the acid leader group, Q² is unsubstituted.

* * *

AMENDED SHEET

181. A compound according to any one of claims 153 to 180, wherein:
A is C₅₋₂₀heteroaryl or C₅₋₂₀carboaryl, and is optionally substituted.
182. A compound according to any one of claims 153 to 180, wherein:
A is a C₅₋₂₀aryl group derived from one of the following:
benzene, pyridine, furan, indole, pyrrole, imidazole, naphthalene, quinoline, benzimidazole, benzothiophuran, fluorene, acridine, and carbazole.
183. A compound according to any one of claims 153 to 180, wherein:
A is an optionally substituted phenyl group.
184. A compound according to any one of claims 153 to 180, wherein:
A is a phenyl group optionally substituted with one or more of the following groups:
fluoro, chloro, bromo, iodo, methyl, ethyl, isopropyl, t-butyl, cyano, trifluoromethyl, hydroxy, methoxy, ethoxy, isopropoxy, trifluoromethoxy, phenoxy, methylthio, trifluoromethylthio, hydroxymethyl, amino, dimethylamino, diethylamino, morpholino, amido, acetamido, acetyl, nitro, sulfonamido, and phenyl.

* * *

185. A compound according to any one of claims 153 to 184, wherein:
the sulfonamido substituent, R¹, is hydrogen, C₁₋₇alkyl, or C₅₋₂₀aryl.
186. A compound according to any one of claims 153 to 184, wherein:
the sulfonamido substituent, R¹, is hydrogen or C₁₋₇alkyl.
187. A compound according to any one of claims 153 to 184, wherein:
the sulfonamido substituent, R¹, is -H, -Me, or -Et.
188. A compound according to any one of claims 153 to 184, wherein:
the sulfonamido substituent, R¹, is -H.

AMENDED SHEET

- 276 -


189. Compound PX117233.
190. Compound PX117234.
191. Compound PX117235.
192. Compound PX117236.
193. Compound PX117245.
194. Compound PX117260.
195. Compound PX117410.
196. Compound PX117411.
197. Compound PX117412.
198. Compound PX117414.

AMENDED SHEET

WJW/LP5958467 - PCT Claims filed under Article 34 in Oct 2002 and before examination

- 277 -

199. A compound of the formula:





wherein:


A is an aryl group;

Q¹ is a covalent bond or an aryl leader group;

J is a sulfonamide linkage selected from:

R¹ is a sulfonamido substituent; and,Q² is an acid leader group;

with the proviso that if J is:

then Q¹ is an aryl leader group;

and wherein:

A, is a C₅₋₂₀aryl group, and is optionally substituted;the aryl leader group, if present, is a C₁₋₇alkylene group and is optionally substituted;the sulfonamido substituent, R¹, is:

hydrogen,

C₁₋₇alkyl,C₃₋₂₀heterocyclyl, orC₅₋₂₀aryl;the acid leader group, Q², is:an ether linkage, -R²-X-R³-, wherein:

X is -O- or -S-; and;

each R² and R³ is independently a C₁₋₇alkylene group, and is optionally substituted;

AMENDED SHEET

- 278 -

and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.

200. A compound according to claim 199, wherein J is $-\text{S}(=\text{O})_2\text{NR}^1-$.
201. A compound according to claim 199, wherein J is $-\text{NR}^1\text{S}(=\text{O})_2-$.
202. A compound according to any one of claims 199 to 201, wherein Q^1 is a covalent bond.
203. A compound according to any one of claims 199 to 201, wherein Q^1 is an aryl leader group.
204. A compound according to any one of claims 199 to 201, wherein Q^1 is an aryl leader group and has a backbone of at least 2 carbon atoms.

- 279 -

* * *

205. A composition comprising a compound according to any one of claims 1 to 209 and a pharmaceutically acceptable carrier or diluent.
206. A compound according to any one of claims 1 to 209 for use in a method of treatment of the human or animal body.
207. A compound according to any one of claims 1 to 209 for use in a method of treatment of a condition mediated by HDAC of the human or animal body.
208. A compound according to any one of claims 1 to 209 for use in a method of treatment of a proliferative condition of the human or animal body.
209. A compound according to any one of claims 1 to 209 for use in a method of treatment of cancer of the human or animal body.
210. A compound according to any one of claims 1 to 209 for use in a method of treatment of psoriasis of the human or animal body.
211. Use of a compound according to any one of claims 1 to 209 for the manufacture of a medicament for use in the treatment of a condition mediated by HDAC.
212. Use of a compound according to any one of claims 1 to 209 for the manufacture of a medicament for use in the treatment of a proliferative condition.
213. Use of a compound according to any one of claims 1 to 209 for the manufacture of a medicament for use in the treatment of cancer.
214. Use of a compound according to any one of claims 1 to 209 for the manufacture of a medicament for use in the treatment of psoriasis.

AMENDED SHEET

WJW/LP5958467 - PCT Claims filed under Article 34 in Oct 2002 and before examination

- 280 -

215. A method inhibiting HDAC in a cell comprising said cell with an effective amount of a compound according to any one of claims 1 to 209.
216. A method for the treatment of a condition mediated by HDAC comprising administering to a subject suffering from a condition mediated by HDAC a therapeutically-effective amount of a compound according to any one of claims 1 to 209.
217. A method for the treatment of a proliferative condition comprising administering to a subject suffering from a proliferative condition a therapeutically-effective amount of a compound according to any one of claims 1 to 209.
218. A method for the treatment of cancer comprising administering to a subject suffering from cancer a therapeutically-effective amount of a compound according to any one of claims 1 to 209.
219. A method for the treatment of psoriasis comprising administering to a subject suffering from psoriasis a therapeutically-effective amount of a compound according to any one of claims 1 to 209.

* * *

AMENDED SHEET